Oxybutynin transdermal - Hisamitsu

Drug Profile

Oxybutynin transdermal - Hisamitsu

Alternative Names: HOB-294; Neoxy Tape

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder

Most Recent Events

  • 17 Mar 2016 Hisamitsu and Asahi Kasei agree to discontinue joint sales of NEOXY® Tape 73.5 mg for Overactive bladder in Japan
  • 25 Mar 2013 Registered for Overactive bladder in Japan (Transdermal)
  • 10 Dec 2012 Oxybutynin transdermal licensed to Asahi Kasei Pharma in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top